Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capio in conjunction with its acquisition of PR Vård
Mandate

Vinge advises Capio in conjunction with its acquisition of PR Vård

March 31, 2022 Employment and Benefits IT, Telecommunications and Outsourcing EU, Competition and Regulatory M&A Public Procurement

Vinge is advising Capio in connection with its acquisition of all shares in PR Vård Hemsjukvåd AB and PR Vård Mottagning AB.

PR Vård conducts home healthcare operations in five out of eight primary health areas in Stockholm as well as one surgery for children and young people and one healthcare surgery in Södermalm. PR Vård has 600 employees and performs approximately 1 million home healthcare visits per year. The acquisition is subject to approval by the Swedish Competition Authority.

Vinge’s team consisted of partner Anders Strid and Jenny Sandlund (project manager), Victoria Gunnerek (public procurement), Adam Löwenstein (tenancy law), Alexander Lindeberg (IT/GDPR), Anna Ståhlklo (employment law), Fredrik Löwenklou (M&A) as well as Anna Palmérus (competition law).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026